Inventiva (NASDAQ:IVA) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Inventiva (NASDAQ:IVA) to a strong-buy rating in a report published on Monday morning,Zacks.com reports.

A number of other analysts have also commented on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Leerink Partners assumed coverage on shares of Inventiva in a research note on Monday. They set an “outperform” rating and a $12.00 target price for the company. UBS Group initiated coverage on Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Wall Street Zen upgraded Inventiva to a “hold” rating in a research note on Saturday, October 18th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Inventiva currently has an average rating of “Buy” and a consensus target price of $16.00.

Inventiva Trading Up 4.7%

NASDAQ IVA opened at $5.98 on Monday. Inventiva has a one year low of $2.11 and a one year high of $7.98. The stock has a 50-day moving average of $4.42 and a 200 day moving average of $4.53.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning bought a new stake in Inventiva during the second quarter valued at about $32,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inventiva by 54.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after acquiring an additional 5,843 shares during the period. NewEdge Advisors LLC purchased a new stake in Inventiva in the 3rd quarter worth approximately $116,000. Finally, Millennium Management LLC purchased a new stake in Inventiva in the 3rd quarter worth approximately $649,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.